[EN] BIARYL SULFONAMIDES AS MMP INHIBITORS<br/>[FR] SULFONAMIDES BIARYLIQUES INHIBITEURS DE MMP
申请人:WYETH CORP
公开号:WO2005061477A1
公开(公告)日:2005-07-07
The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors: Formule (I).
本发明涉及联苯磺酰胺及其用途,例如,作为金属蛋白酶抑制剂:式(I)。
Biaryl Sulfonamides and Methods for Using Same
申请人:Levin Jeremy Ian
公开号:US20100137298A1
公开(公告)日:2010-06-03
The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
本发明涉及双芳基磺酰胺及其用途,例如作为金属蛋白酶抑制剂。
3,4-Disubstituted benzofuran P1′ MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding
作者:Wei Li、Yonghan Hu、Jianchang Li、Jennifer R. Thomason、Dianne DeVincentis、Xuemei Du、Junjun Wu、Rajeev Hotchandani、Thomas S. Rush、Jerauld S. Skotnicki、Steve Tam、Priya S. Chockalingam、Elisabeth A. Morris、Jeremy I. Levin
DOI:10.1016/j.bmcl.2009.07.008
日期:2009.8
Potent 3,4-disubstituted benzofuran P1' MMP-13 inhibitors have been prepared. Selectivity over MMP-2 was achieved through a substituent at the C4 position of the benzofuran P1' moiety of the molecule. By replacing a backbone benzene with a pyridine and valine with threonine, compounds (e. g., 44) with greatly reduced plasma protein binding were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.